- Home
- AMSC vs IMCR Comparison
AMSC vs IMCR Comparison
Compare AMSC & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AMSC | IMCR |
|---|---|---|
| Founded | 1987 | 2008 |
| Country | United States | United Kingdom |
| Employees | 400 | N/A |
| Industry | Metal Fabrications | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | 2012 | 2016 |
Fundamental Metrics
Financial Performance| Metric | AMSC | IMCR |
|---|---|---|
| Price | $28.79 | $29.59 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 12 |
| Target Price | $52.00 | ★ $61.82 |
| AVG Volume (30 Days) | ★ 685.0K | 349.0K |
| Earning Date | 02-04-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 143.24 | 30.39 |
| EPS | ★ 3.01 | N/A |
| Revenue | $900,000.00 | ★ $249,428,000.00 |
| Revenue This Year | $34.98 | $14.39 |
| Revenue Next Year | $21.38 | $8.19 |
| P/E Ratio | $10.18 | ★ N/A |
| Revenue Growth | N/A | ★ 43.05 |
| 52 Week Low | $13.98 | $23.15 |
| 52 Week High | $70.49 | $40.71 |
Technical Indicators
Market Signals| Indicator | AMSC | IMCR |
|---|---|---|
| Relative Strength Index (RSI) | 42.43 | 34.86 |
| Support Level | $25.84 | N/A |
| Resistance Level | $34.14 | $34.35 |
| Average True Range (ATR) | 1.69 | 1.37 |
| MACD | -0.14 | -0.26 |
| Stochastic Oscillator | 33.91 | 3.46 |
Price Performance
Historical ComparisonAbout AMSC American Superconductor Corporation
American Superconductor Corp generates the ideas, technologies, and solutions that meet the world's demand for smarter, cleaner, and energy. Through its Windtec Solutions, the company enables manufacturers to launch wind turbines quickly, effectively, and profitably. Through its Gridtec Solutions, the company provides engineering planning services and grid systems that optimize network reliability, efficiency, and performance. The company's segment includes Grid and Wind. It generates maximum revenue from the Grid segment.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.